The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

Excess body weight is a global health problem due to sedentary lifestyle and unhealthy diet,
affecting 2 billion population worldwide. Obesity is a major risk factor for metabolic diseases …

Background Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic
polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response …

Background According to current consensus guidelines for type 2 diabetes management,
bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single …

Background Treating hyperglycaemia and obesity in individuals with type 2 diabetes using
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing
need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) …

Obesity is a chronic, progressive and relapsing disease with a rising global prevalence
associated with increased morbidity and mortality and reduced quality of life. Treatment of …

The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide
1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate …

Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …

Long-acting analogues of the naturally occurring incretin, glucagon-like peptide-1 (GLP-1)
and those modified to interact also with receptors for glucose-dependent insulinotropic …